

September 9, 2022

BSE Limited Code: 532321

1st Floor. P J Towers. Dalal Street, Mumbai-400001

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai-400051

Re.: Press Release

Dear Sir / Madam,

Please find enclosed copy of press release dated September 9, 2022 titled "Zydus in-licenses a critical drug for CKD patients from Pharmacosmos A/S of Denmark".

Code: Zyduslife

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully, For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above

website: www.zyduslife.com | CIN: L24230GJ1995PLC025878



Zydus in-licenses a critical drug for CKD patients from Pharmacosmos A/S of Denmark

September 09, 2022, Ahmedabad, India

Zydus Lifesciences Ltd., an innovation-driven global lifesciences announced that it has acquired rights to market MonoFerric® (iron isomaltoside) injections in India and Nepal from Denmark based Pharmacosmos A/S. MonoFerric®, iron isomaltoside 1000 solution for injection/infusion, is a rapid, single dose IV iron (up to 20 mg/kg bodyweight) developed to reduce the number of infusions required to achieve iron correction with an excellent safety profile. MonoFerric® is indicated for the treatment of iron deficiency in adult patients when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly. MonoFerric® is available in over 30 countries including US and Europe and over 28 million doses have been administered since launch.

Speaking on the development Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd. said, "Iron Deficiency is a severe healthcare challenge and also impacts the quality of life more so in CKD patients. With this introduction, we bring a novel solution to these patients and with our strong last-mile delivery, we will enable access to this critical therapy."

Zydus is amongst the top players in the Nephrology segment with a super-specialty portfolio with brands like Oxemia, Zyrop, Renocrit, Kbind, Grafalon, Tacromus and Mycomune.

About Zydus

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. For more details visit www.zyduslife.com.

About Pharmacosmos A/S

Pharmacosmos A/S is a specialist in iron therapy developing, manufacturing and marketing medicines for the treatment of iron deficiency anemia in humans and animals. Furthermore, the company specialises in developing and producing advanced carbohydrates for pharmaceutical and technical uses. Headquartered in Holbæk, Denmark and affiliates in the US, China, UK, Ireland, Germany, Sweden and Norway, Pharmacosmos has grown considerably over the years and has at present more than 500 people working with all aspects of a fully integrated pharmaceutical company. For more information visit www.pharmacosmos.com



For further information please contact: The Corporate Communications Department

Zydus Lifesciences Limited

(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',

Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, Gujarat, India. | Phone: +91-79-71800000, +91-79-48040000 | website: www.zyduslife.com

CIN: L24230GJ1995PLC025878